Imidapril

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Imidapril
Accession Number
DB11783
Type
Small Molecule
Groups
Investigational
Description

Imidapril has been investigated for the treatment of Kidney, Polycystic, Autosomal Dominant.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Imidapril Hydrochloride7NSF9GG1NU89396-94-1LSLQGMMMRMDXHN-GEUPQXMHSA-N
Categories
UNII
BW7H1TJS22
CAS number
89371-37-9
Weight
Average: 405.4449
Monoisotopic: 405.189985611
Chemical Formula
C20H27N3O6
InChI Key
KLZWOWYOHUKJIG-BPUTZDHNSA-N
InChI
InChI=1S/C20H27N3O6/c1-4-29-19(27)15(11-10-14-8-6-5-7-9-14)21-13(2)17(24)23-16(18(25)26)12-22(3)20(23)28/h5-9,13,15-16,21H,4,10-12H2,1-3H3,(H,25,26)/t13-,15-,16-/m0/s1
IUPAC Name
(4S)-3-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-1-methyl-2-oxoimidazolidine-4-carboxylic acid
SMILES
[H][[email protected]@](C)(N[[email protected]@]([H])(CCC1=CC=CC=C1)C(=O)OCC)C(=O)N1C(=O)N(C)C[[email protected]@]1([H])C(O)=O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Imidapril.Investigational
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Imidapril.Experimental
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Imidapril.Approved, Investigational
AcebutololAcebutolol may increase the hypotensive activities of Imidapril.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Imidapril.Approved, Investigational
AcemetacinThe therapeutic efficacy of Imidapril can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
Acetylsalicylic acidThe therapeutic efficacy of Imidapril can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Imidapril.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Imidapril.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Imidapril is combined with Aldesleukin.Approved
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Imidapril.Approved, Investigational
AliskirenAliskiren may increase the hypotensive, nephrotoxic, and hyperkalemic activities of Imidapril.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Imidapril.Approved
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Imidapril.Experimental
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Imidapril.Approved
AloxiprinThe therapeutic efficacy of Imidapril can be decreased when used in combination with Aloxiprin.Experimental
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Imidapril.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Imidapril.Approved, Withdrawn
AmbrisentanImidapril may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Imidapril.Experimental, Investigational
AmifostineImidapril may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideAmiloride may increase the hyperkalemic activities of Imidapril.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Imidapril.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Imidapril.Approved
Aminosalicylic AcidThe therapeutic efficacy of Imidapril can be decreased when used in combination with Aminosalicylic Acid.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Imidapril.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Imidapril.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Imidapril.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Imidapril.Approved, Illicit
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with Imidapril.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Imidapril.Approved, Illicit, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Imidapril.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Imidapril is combined with Amyl Nitrite.Approved
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Imidapril.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Imidapril.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Imidapril.Approved, Investigational
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Imidapril.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Imidapril.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Imidapril is combined with Apraclonidine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Imidapril.Approved, Investigational
AprotininAprotinin may decrease the antihypertensive activities of Imidapril.Approved, Investigational, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Imidapril.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Imidapril.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Imidapril.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Imidapril.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Imidapril.Approved
AvanafilAvanafil may increase the antihypertensive activities of Imidapril.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Imidapril.Withdrawn
AzathioprineThe risk or severity of anemia and severe leukopenia can be increased when Imidapril is combined with Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Imidapril.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Imidapril.Approved, Investigational
AzosemideAzosemide may increase the hypotensive activities of Imidapril.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Imidapril.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Imidapril.Experimental
BarbitalBarbital may increase the hypotensive activities of Imidapril.Illicit
BarnidipineImidapril may increase the antihypertensive activities of Barnidipine.Approved
BenazeprilBenazepril may increase the hypotensive activities of Imidapril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Imidapril.Experimental
BendroflumethiazideThe risk or severity of hypotension can be increased when Bendroflumethiazide is combined with Imidapril.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Imidapril.Withdrawn
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Imidapril.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Imidapril.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Imidapril.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Imidapril.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Imidapril.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Imidapril.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Imidapril.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Imidapril.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Imidapril.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Imidapril.Approved
BoceprevirThe serum concentration of Imidapril can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Imidapril.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Imidapril.Approved, Investigational
BQ-123Imidapril may increase the hypotensive activities of BQ-123.Investigational
BretyliumBretylium may increase the hypotensive activities of Imidapril.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Imidapril.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Imidapril.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Imidapril.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Imidapril.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Imidapril.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Imidapril.Approved, Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Imidapril.Experimental
BumetanideBumetanide may increase the hypotensive activities of Imidapril.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Imidapril.Approved, Investigational
BupranololBupranolol may increase the hypotensive activities of Imidapril.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Imidapril.Approved
CadralazineCadralazine may increase the hypotensive activities of Imidapril.Experimental
CafedrineImidapril may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinThe risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Imidapril.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Imidapril.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Imidapril.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Imidapril.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Imidapril.Approved
CarbamazepineThe metabolism of Imidapril can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe therapeutic efficacy of Imidapril can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Imidapril.Approved, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Imidapril.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Imidapril.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Imidapril.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Imidapril.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Imidapril.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Imidapril.Approved, Investigational
CeliprololCeliprolol may increase the hypotensive activities of Imidapril.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Imidapril.Approved, Investigational, Vet Approved
ChlorothiazideThe risk or severity of hypotension can be increased when Chlorothiazide is combined with Imidapril.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Imidapril.Investigational, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Imidapril.Approved, Investigational, Vet Approved
ChlorthalidoneThe risk or severity of hypotension can be increased when Chlorthalidone is combined with Imidapril.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Imidapril.Approved
CicletanineImidapril may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilCilazapril may increase the hypotensive activities of Imidapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Imidapril.Approved, Investigational
CiprofloxacinThe risk or severity of ventricular arrhythmias can be increased when Imidapril is combined with Ciprofloxacin.Approved, Investigational
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Imidapril.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Imidapril is combined with Clevidipine.Approved, Investigational
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Imidapril.Approved, Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Imidapril.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Imidapril.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Imidapril.Approved
CloranololImidapril may increase the hypotensive activities of Cloranolol.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Imidapril.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Imidapril.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be decreased when it is combined with Imidapril.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Imidapril.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Imidapril.Approved, Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Imidapril.Approved
CyclopenthiazideThe risk or severity of hypotension can be increased when Cyclopenthiazide is combined with Imidapril.Experimental
CyclophosphamideThe risk or severity of adverse effects can be increased when Imidapril is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Imidapril.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Imidapril.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Imidapril is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Imidapril.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Imidapril.Approved, Investigational
DelaprilImidapril may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Imidapril.Approved
DersalazineThe therapeutic efficacy of Imidapril can be decreased when used in combination with Dersalazine.Investigational
DeserpidineImidapril may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Imidapril.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Imidapril.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Imidapril is combined with Dexmedetomidine.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Imidapril.Approved
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Imidapril.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Imidapril.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Imidapril is combined with Diclofenamide.Approved, Investigational
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Imidapril.Approved, Investigational
DiethylnorspermineDiethylnorspermine may increase the hypotensive activities of Imidapril.Investigational
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Imidapril.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Imidapril.Experimental
DiflunisalThe therapeutic efficacy of Imidapril can be decreased when used in combination with Diflunisal.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Imidapril.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Imidapril.Approved, Investigational
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Imidapril.Approved, Investigational
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Imidapril.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Imidapril is combined with Dinutuximab.Approved, Investigational
DipyridamoleThe risk or severity of adverse effects can be increased when Imidapril is combined with Dipyridamole.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Imidapril.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Imidapril.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Imidapril.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Imidapril.Approved, Investigational
DrospirenoneImidapril may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Imidapril.Withdrawn
DuloxetineImidapril may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Imidapril.Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Imidapril.Approved
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Imidapril.Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Imidapril.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Imidapril is combined with Empagliflozin.Approved
EnalaprilEnalapril may increase the hypotensive activities of Imidapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Imidapril.Approved
EndralazineEndralazine may increase the hypotensive activities of Imidapril.Experimental
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Imidapril.Approved, Investigational
EpanololImidapril may increase the hypotensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Imidapril.Approved
EpitizideThe risk or severity of hypotension can be increased when Epitizide is combined with Imidapril.Experimental
EplerenoneEplerenone may increase the hyperkalemic activities of Imidapril.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Imidapril.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Imidapril.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Imidapril.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Imidapril.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Imidapril.Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Imidapril.Investigational
EsmololThe risk or severity of adverse effects can be increased when Imidapril is combined with Esmolol.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Imidapril.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Imidapril.Approved, Investigational
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Imidapril.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Imidapril.Approved
Etacrynic acidEtacrynic acid may increase the hypotensive activities of Imidapril.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Imidapril.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Imidapril.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Imidapril.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Imidapril.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Imidapril.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Imidapril.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Imidapril.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Imidapril.Approved, Investigational
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Imidapril.Approved
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Imidapril.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Imidapril.Experimental
FelodipineFelodipine may increase the hypotensive activities of Imidapril.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Imidapril.Approved
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Imidapril.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Imidapril.Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Imidapril.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Imidapril.Experimental
Ferulic acidFerulic acid may increase the hypotensive activities of Imidapril.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Imidapril.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Imidapril.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Imidapril.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Imidapril.Experimental
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Imidapril.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Imidapril.Experimental
FosinoprilFosinopril may increase the hypotensive activities of Imidapril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Imidapril.Approved, Investigational, Vet Approved
FurosemideFurosemide may increase the hypotensive activities of Imidapril.Approved, Vet Approved
GarlicThe serum concentration of Imidapril can be decreased when it is combined with Garlic.Approved
GuacetisalThe therapeutic efficacy of Imidapril can be decreased when used in combination with Guacetisal.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Imidapril.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Imidapril.Approved
GuanazodineImidapril may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Imidapril.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Imidapril.Approved, Investigational
GuanoclorImidapril may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzImidapril may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanImidapril may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Imidapril.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Imidapril.Experimental
Hemoglobin crosfumarilThe therapeutic efficacy of Imidapril can be decreased when used in combination with Hemoglobin crosfumaril.Experimental
HeparinThe risk or severity of hyperkalemia can be increased when Imidapril is combined with Heparin.Approved, Investigational
HexamethoniumHexamethonium may increase the hypotensive activities of Imidapril.Experimental
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Imidapril.Withdrawn
HexobarbitalHexobarbital may increase the hypotensive activities of Imidapril.Approved
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Imidapril.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Imidapril.Experimental
HydralazineHydralazine may increase the hypotensive activities of Imidapril.Approved
HydrochlorothiazideThe risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Imidapril.Approved, Vet Approved
HydroflumethiazideThe risk or severity of hypotension can be increased when Hydroflumethiazide is combined with Imidapril.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Imidapril.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Imidapril.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Imidapril.Approved, Investigational
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Imidapril.Approved, Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Imidapril.Experimental
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Imidapril.Approved
IndapamideThe risk or severity of hypotension can be increased when Indapamide is combined with Imidapril.Approved
IndenololIndenolol may increase the hypotensive activities of Imidapril.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Imidapril.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Imidapril.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Imidapril.Withdrawn
IndoraminThe risk or severity of adverse effects can be increased when Imidapril is combined with Indoramin.Withdrawn
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Imidapril.Experimental
IproclozideIproclozide may increase the hypotensive activities of Imidapril.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Imidapril.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Imidapril.Approved, Investigational
IronIron can cause a decrease in the absorption of Imidapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Imidapril is combined with Iron Dextran.Approved, Vet Approved
IsocarboxazidThe risk or severity of adverse effects can be increased when Imidapril is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Imidapril is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Imidapril is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Imidapril is combined with Isosorbide Mononitrate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Imidapril.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Imidapril is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Imidapril.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Imidapril.Experimental
KetanserinKetanserin may increase the hypotensive activities of Imidapril.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Imidapril.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Imidapril.Approved
LabetalolLabetalol may increase the hypotensive activities of Imidapril.Approved
LacidipineImidapril may increase the hypotensive activities of Lacidipine.Approved, Investigational
Lanthanum carbonateThe serum concentration of Imidapril can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Imidapril.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Imidapril.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Imidapril is combined with Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Imidapril is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Imidapril is combined with Levobupivacaine.Approved, Investigational
LevodopaImidapril may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Imidapril is combined with Levosimendan.Approved, Investigational
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Imidapril.Approved
LinsidomineImidapril may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Imidapril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Imidapril.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Imidapril.Approved
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Imidapril.Experimental
LofexidineThe risk or severity of adverse effects can be increased when Imidapril is combined with Lofexidine.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Imidapril.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Imidapril.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Imidapril.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Imidapril.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Imidapril.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Imidapril.Approved, Investigational
MacitentanImidapril may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Imidapril.Approved
ManidipineManidipine may increase the hypotensive activities of Imidapril.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Imidapril is combined with Mannitol.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Imidapril.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Imidapril.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Imidapril.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Imidapril.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Imidapril.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Imidapril.Approved, Vet Approved
MesalazineThe therapeutic efficacy of Imidapril can be decreased when used in combination with Mesalazine.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Imidapril.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Imidapril.Approved, Investigational, Withdrawn
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Imidapril.Experimental
MethazolamideThe risk or severity of adverse effects can be increased when Imidapril is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Imidapril.Approved
MethoserpidineImidapril may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of hypotension can be increased when Methyclothiazide is combined with Imidapril.Approved
Methyl salicylateThe therapeutic efficacy of Imidapril can be decreased when used in combination with Methyl salicylate.Approved, Vet Approved
MethyldopaMethyldopa may increase the hypotensive activities of Imidapril.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Imidapril.Approved, Investigational
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Imidapril.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Imidapril.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Imidapril.Approved
MetipranololMetipranolol may increase the hypotensive activities of Imidapril.Approved
MetolazoneThe risk or severity of hypotension can be increased when Metolazone is combined with Imidapril.Approved
MetoprololMetoprolol may increase the hypotensive activities of Imidapril.Approved, Investigational
MetyrosineImidapril may increase the hypotensive activities of Metyrosine.Approved
MibefradilMibefradil may increase the hypotensive activities of Imidapril.Investigational, Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Imidapril.Approved, Illicit
MinaprineMinaprine may increase the hypotensive activities of Imidapril.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Imidapril.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Imidapril.Investigational
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Imidapril.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Imidapril.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Imidapril.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Imidapril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Imidapril.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Imidapril.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Imidapril is combined with Morphine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Imidapril is combined with Moxonidine.Approved, Investigational
MuzolimineImidapril may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Imidapril.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Imidapril.Approved
NabiloneThe risk or severity of adverse effects can be increased when Imidapril is combined with Nabilone.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Imidapril.Approved
NadololNadolol may increase the hypotensive activities of Imidapril.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Imidapril.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Imidapril.Approved
NaftopidilImidapril may increase the hypotensive activities of Naftopidil.Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Imidapril.Approved, Vet Approved
NebivololNebivolol may increase the hypotensive activities of Imidapril.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Imidapril.Approved, Withdrawn
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Imidapril.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Imidapril is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Imidapril.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Imidapril.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Imidapril.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Imidapril is combined with Nifedipine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Imidapril.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Imidapril.Approved
NiguldipineNiguldipine may increase the hypotensive activities of Imidapril.Experimental
NilvadipineThe risk or severity of adverse effects can be increased when Imidapril is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Imidapril.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Imidapril.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Imidapril.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Imidapril is combined with Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Imidapril is combined with Nitric Oxide.Approved
NitroaspirinThe therapeutic efficacy of Imidapril can be decreased when used in combination with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Imidapril is combined with Nitroglycerin.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Imidapril.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Imidapril is combined with Nitrous acid.Approved, Investigational
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Imidapril.Approved
ObinutuzumabImidapril may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Imidapril.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Imidapril.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Imidapril.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Imidapril.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Imidapril.Investigational
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Imidapril.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Imidapril.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Imidapril.Approved
OxprenololThe risk or severity of adverse effects can be increased when Imidapril is combined with Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Imidapril.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Imidapril is combined with Paclitaxel.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Imidapril is combined with Papaverine.Approved, Investigational
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Imidapril.Approved
PargylinePargyline may increase the hypotensive activities of Imidapril.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Imidapril.Approved, Investigational
Patent BlueThe therapeutic efficacy of Imidapril can be decreased when used in combination with Patent Blue.Approved
PenbutololPenbutolol may increase the hypotensive activities of Imidapril.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Imidapril.Approved, Investigational, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Imidapril.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Imidapril.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Imidapril.Approved
PethidineThe risk or severity of adverse effects can be increased when Imidapril is combined with Pethidine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Imidapril is combined with Phenelzine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Imidapril.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Imidapril.Approved, Investigational
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Imidapril is combined with Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Imidapril.Withdrawn
PhentolamineThe risk or severity of adverse effects can be increased when Imidapril is combined with Phentolamine.Approved
Phenyl aminosalicylateThe therapeutic efficacy of Imidapril can be decreased when used in combination with Phenyl aminosalicylate.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Imidapril.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Imidapril.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Imidapril.Approved
PindololPindolol may increase the hypotensive activities of Imidapril.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Imidapril is combined with Pipamperone.Approved, Investigational
PiretanidePiretanide may increase the hypotensive activities of Imidapril.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Imidapril.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Imidapril.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Imidapril.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Imidapril.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Imidapril.Withdrawn
Platelet Activating FactorPlatelet Activating Factor may increase the hypotensive activities of Imidapril.Experimental
PolythiazideThe risk or severity of hypotension can be increased when Polythiazide is combined with Imidapril.Approved
PotassiumPotassium may increase the hyperkalemic activities of Imidapril.Approved, Investigational
Potassium bicarbonatePotassium bicarbonate may increase the hyperkalemic activities of Imidapril.Approved
Potassium ChloridePotassium Chloride may increase the hyperkalemic activities of Imidapril.Approved, Withdrawn
Potassium CitratePotassium Citrate may increase the hyperkalemic activities of Imidapril.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Imidapril is combined with Pramipexole.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Imidapril.Experimental, Investigational
PrazosinPrazosin may increase the hypotensive activities of Imidapril.Approved
PregabalinThe risk or severity of angioedema can be increased when Imidapril is combined with Pregabalin.Approved, Illicit, Investigational
PrimidonePrimidone may increase the hypotensive activities of Imidapril.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Imidapril.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Imidapril.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Imidapril.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Imidapril is combined with Propofol.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the hypotensive activities of Imidapril.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Imidapril.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Imidapril.Experimental
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Imidapril.Approved
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Imidapril.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Imidapril is combined with Quetiapine.Approved
QuinaprilQuinapril may increase the hypotensive activities of Imidapril.Approved, Investigational
QuinethazoneThe risk or severity of hypotension can be increased when Quinethazone is combined with Imidapril.Approved
QuinineQuinine may increase the hypotensive activities of Imidapril.Approved
RamiprilRamipril may increase the hypotensive activities of Imidapril.Approved
RasagilineThe risk or severity of adverse effects can be increased when Imidapril is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Imidapril is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Imidapril.Approved
RescinnamineImidapril may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Imidapril.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Imidapril.Approved, Experimental, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Imidapril.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Imidapril.Approved
RisperidoneImidapril may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabImidapril may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Imidapril.Approved, Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Imidapril is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Imidapril is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Imidapril is combined with Rotigotine.Approved
SacubitrilThe risk or severity of angioedema can be increased when Imidapril is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Imidapril.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Imidapril.Approved
Salicylic acidThe therapeutic efficacy of Imidapril can be decreased when used in combination with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Imidapril.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Imidapril.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Imidapril.Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Imidapril.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Imidapril.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Imidapril is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagSelexipag may increase the hypotensive activities of Imidapril.Approved
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Imidapril.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Imidapril.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Imidapril.Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Imidapril is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Imidapril.Approved, Investigational
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Imidapril.Approved
SirolimusThe risk or severity of angioedema can be increased when Sirolimus is combined with Imidapril.Approved, Investigational
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Imidapril.Approved, Investigational
SitaxentanImidapril may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of hypotension, nitritoid reactions, facial flushing, nausea, and vomiting can be increased when Imidapril is combined with Sodium aurothiomalate.Approved, Investigational
Sodium phosphateImidapril may increase the nephrotoxic activities of Sodium phosphate.Approved
SotalolThe risk or severity of adverse effects can be increased when Imidapril is combined with Sotalol.Approved
SpiraprilSpirapril may increase the hypotensive activities of Imidapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Imidapril is combined with Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Imidapril.Investigational
St. John's WortThe metabolism of Imidapril can be increased when combined with St. John's Wort.Approved, Investigational, Nutraceutical
StreptokinaseThe risk or severity of adverse effects can be increased when Imidapril is combined with Streptokinase.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Imidapril is combined with Sufentanil.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Imidapril.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Imidapril.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Imidapril.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Imidapril.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Imidapril.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Imidapril.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Imidapril.Approved, Investigational
TalinololTalinolol may increase the hypotensive activities of Imidapril.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Imidapril is combined with Tamsulosin.Approved, Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Imidapril.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Imidapril.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Imidapril.Approved, Investigational
TemocaprilTemocapril may increase the hypotensive activities of Imidapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Imidapril is combined with Temsirolimus.Approved
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Imidapril.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Imidapril.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Imidapril.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Imidapril is combined with Terazosin.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Imidapril.Approved
TerlipressinTerlipressin may increase the hypotensive activities of Imidapril.Approved, Investigational
TetrahydropalmatineImidapril may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Imidapril is combined with Thalidomide.Approved, Investigational, Withdrawn
TheodrenalineImidapril may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Imidapril.Approved
ThiamylalThiamylal may increase the hypotensive activities of Imidapril.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Imidapril.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Imidapril is combined with Thioridazine.Approved, Withdrawn
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Imidapril.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Imidapril.Approved
TiboloneTibolone may increase the hypotensive activities of Imidapril.Approved, Investigational
TicrynafenTicrynafen may increase the hypotensive activities of Imidapril.Withdrawn
TimololTimolol may increase the hypotensive activities of Imidapril.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Imidapril.Investigational
TipranavirThe serum concentration of Imidapril can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of hypotension can be increased when Tizanidine is combined with Imidapril.Approved, Investigational
TolazolineThe risk or severity of adverse effects can be increased when Imidapril is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Imidapril is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Imidapril.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Imidapril.Approved
TolonidineImidapril may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Imidapril.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Imidapril.Approved
TorasemideTorasemide may increase the hypotensive activities of Imidapril.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Imidapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Imidapril.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Imidapril is combined with Tranylcypromine.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Imidapril.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Imidapril.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Imidapril is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneTriamterene may increase the hyperkalemic activities of Imidapril.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Imidapril.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Imidapril.Experimental
TrichlormethiazideThe risk or severity of hypotension can be increased when Trichlormethiazide is combined with Imidapril.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Imidapril.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Imidapril.Approved, Investigational
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Imidapril.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Imidapril.Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Imidapril.Investigational
Trolamine salicylateThe therapeutic efficacy of Imidapril can be decreased when used in combination with Trolamine salicylate.Approved
UdenafilUdenafil may increase the antihypertensive activities of Imidapril.Approved, Investigational
UnoprostoneUnoprostone may increase the hypotensive activities of Imidapril.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Imidapril.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Imidapril.Approved, Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Imidapril.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Imidapril.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Imidapril.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Imidapril.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Imidapril.Approved, Investigational
VincamineImidapril may increase the hypotensive activities of Vincamine.Experimental
VinpocetineImidapril may increase the hypotensive activities of Vinpocetine.Investigational
XipamideImidapril may increase the hypotensive activities of Xipamide.Experimental
XylometazolineXylometazoline may increase the hypotensive activities of Imidapril.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Imidapril.Approved, Investigational, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Imidapril.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Imidapril.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Imidapril.Approved, Investigational, Withdrawn
ZofenoprilImidapril may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Imidapril.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0041907
PubChem Compound
5464343
PubChem Substance
347828133
ChemSpider
4576628
BindingDB
50020400
ChEBI
135654
ChEMBL
CHEMBL317094
PharmGKB
PA452640
Wikipedia
Imidapril
ATC Codes
C09AA16 — Imidapril

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Unknown StatusTreatmentAutosomal Dominant Polycystic Kidney Disease (ADPKD)1
3Unknown StatusTreatmentHigh Blood Pressure (Hypertension) / Microalbuminuria / Type 2 Diabetes Mellitus1
3Unknown StatusTreatmentHypertension,Essential1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.447 mg/mLALOGPS
logP0.74ALOGPS
logP-0.23ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)3.49ChemAxon
pKa (Strongest Basic)5.22ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area116.25 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity103.2 m3·mol-1ChemAxon
Polarizability42.29 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Dipeptides
Alternative Parents
Alpha amino acid esters / N-acyl-L-alpha-amino acids / Alpha amino acid amides / N-acyl ureas / Fatty acid esters / Aralkylamines / Imidazolidinones / Dicarboxylic acids and derivatives / Benzene and substituted derivatives / Dicarboximides
show 9 more
Substituents
Alpha-dipeptide / Alpha-amino acid ester / N-acyl-l-alpha-amino acid / Alpha-amino acid amide / Alpha-amino acid or derivatives / N-acyl urea / Fatty acid ester / Ureide / Aralkylamine / Imidazolidinone
show 26 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 14:47 / Updated on May 02, 2018 01:38